Senior Director
Nurix Therapeutics
Senior Director
Nurix Therapeutics
Drug discovery targeting ubiquitin E3 ligases
Senior Director, Quality Control
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.
Position Description
Nurix Therapeutics is seeking an experienced Senior Director, Quality Control to join the Analytical Development and Quality Control group. This individual will establish and lead a QC operational function, establishing operations, systems, and a team to support programs from CMC development through commercial manufacturing.
The ideal candidate brings deep expertise in small molecule QC, strong regulatory acumen, and proven experience managing external CDMO and CTL relationships. This role will represent QC in health authority inspections and audits, and will work cross-functionally with Quality, Analytical Development, and Manufacturing to ensure product quality and patient safety across the portfolio.
Key responsibilities
Qualifications
Fit with Nurix Culture and Values
Salary Range: $280,200 - $319,800
Location: Woodlands TX or Brisbane, CA - Onsite
Drug discovery targeting ubiquitin E3 ligases
Nurix Therapeutics develops drugs that use the body's own protein-degradation system to treat diseases. Its core approach is to control ubiquitin E3 ligases, enzymes that tag unwanted proteins for breakdown in cells. By modulating these ligases, Nurix aims to create therapeutics, especially small-molecule immuno-oncology agents, that can selectively remove disease-related proteins in cancer and other serious conditions. The company operates by discovering and developing drug candidates and earning revenue through partnerships, licensing, and potential future sales of its medicines. Unlike many biotech firms that target single proteins, Nurix focuses on the protein-degradation pathway to influence multiple disease processes through carefully designed molecules. The goal is to bring new cancer treatments and other therapies to patients by advancing its degrader-based drugs through research, collaboration, and development toward commercial use.
Explore more opportunities at Nurix Therapeutics